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Purpose: To test the psychometric properties of the International Prostate Symptom Score Hong 
Kong Chinese version 2 (IPSS) in Chinese male patients with BPH under secondary care. 
 
Methods: A prospective longitudinal study was done by interviewing subjects at baseline, at 2-
week after baseline for assessing test-retest reliability and at 26-week after baseline for assessing 
responsiveness. All subjects were interviewed to complete a structured questionnaire including 
IPSS, Short Frorm-12 Health Survey Version 2 (SF-12v2) and Depression Anxiety Stress Scale 
(DASS). 
 
Results: The IPSS HRQOL score had weak correlations with SF-12v2 summary and DASS 
domain scores. For reliability analysis, Cronbach’s alpha coefficient was 0.90 for the seven 
symptom-related items. The intra-class correlation coefficients of the IPSS total symptom score 
and HRQOL score were 0.90 and 0.86, respectively. For sensitivity, statistically significant 
differences were detected between the subjects with BPH and those without for IPSS total 
symptom score (effect size = 0.68) but not the IPSS HRQOL score. The areas under ROC curves 
for the IPSS total symptom and HRQOL scores were 0.67 and 0.60, respectively.  
 
Conclusions: The IPSS was valid, reliable instrument in Chinese patients with BPH. The IPSS 
total symptom score, but not the HRQOL score, is sensitive in differentiating subgroups. 
 






Benign prostatic hyperplasia (BPH) is a common urological condition among aging males. 
Although many men with a history of BPH and even anatomically enlarged prostates due to this 
condition have no symptoms, more than 50% of men in their 60s to as many as 90% of 
octogenarians present with lower urinary tract symptoms (LUTS)[1]. An epidemiological study in 
Hong Kong suggested that moderate-to-severe LUTS is common in elderly Chinese males while 
the prevalence rate of mild and moderate-to-severe LUTS was 56% and 38.2[2], respectively. 
Furthermore, a population-based study in Canada, Germany, Italy, Sweden, and the United 
Kingdom found that the prevalence of storage LUTS was 51.3%, voiding LUTS was 25.7%, and 
post-micturition LUTS was 16.9% in men [3]. Although LUTS is not a life threatening disease, 
those suffering from LUTS, especially for those with moderate and severe symptoms, have a 
poorer health-related quality of life (HRQOL) [4-6]. 
 
In addition to objective measures such as conducting an uroflowmetry, the severity of LUTS is 
assessed by a self-reported questionnaire. The International Prostate Symptom Score (IPSS) is one 
of the commonly-used questionnaires to assess the severity of LUTS and LUTS-specific HRQOL 
in male patients. The questionnaire was first developed by the American Urological Association 
[7]. The questionnaire is reliable, valid, sensitive and responsive [8]. The World Health 
Organization has subsequently suggested the IPSS is an important instrument in the assessment of 
BPH [9]. The role of the IPSS measurement for LUTS and BPH is well established, attributable in 
part to the evidence linking the severity of LUTS with hormonal status[10-12] and metabolic 
syndrome components[13, 14].  
 
The IPSS was translated into Traditional Chinese by the Hong Kong Urological Association 
(HKUA) in 1995. The content validity and psychometric properties of the Hong Kong Chinese 
version of IPSS were subsequently reviewed by Choi et al [15].  The study by Choi et al found 
that some translations of the original Hong Kong Chinese version of the IPSS were not 
equivalent to the original English version. Modifications were made, resulting in the 
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development of the IPSS Hong Kong Chinese version 2[15]. The content validity, construct 
validity, reliability, sensitivity and responsiveness were evaluated and confirmed in Chinese 
primary care patients [15, 16]. Since the sample of patients taken for the study were Chinese 
primary care patients, the results might not apply to patients under secondary care, the disease 
profile of whom may differ. The lack of knowledge of the psychometric properties of the IPSS 
instrument in patients under secondary care necessitated the present study. 
 
Aims and Objectives 
The aim of this study is to test the psychometric properties of the IPSS instrument in Chinese 
male patients with BPH under secondary care. The objectives are the following: to assess the 
validity of the construct of the IPSS, to assess the reliability of the IPSS, to assess the sensitivity 
of the IPSS, and to assess the responsiveness of the IPSS. 
  





This is a prospective longitudinal study. Subjects were interviewed at the baseline, 2 weeks 
following the baseline to assess the test-retest reliability, and 26 weeks after the baseline to 
assess responsiveness.  
 
Subjects and sampling 
A group of patients with BPH and a group of control subjects without BPH from the urology 
specialist out-patient clinics of three hospitals (Queen Mary Hospital, Tuen Mun Hospital and 
Princess Margaret Hospital) were recruited between June 2014 and December 2014. Patients 
diagnosed and documented with BPH by their physicians were eligible to join the study. Patients 
without a documented diagnosis of lower urinary tract symptoms and benign prostatic 
hyperplasia were eligible to join the control group of the study. Patients aged < 18 years, those 
who could not understand Cantonese, or were too ill to give consent, had cognitive impairment 
or dementia, or refused to join the study were excluded from both groups. 
 
Procedure 
Trained field workers approached eligible patients in three urology specialist out-patient clinics 
(one clinic per hospital) to invite them to participate in this observational study. The aims, 
objectives, procedures and nature of the study were explained before obtaining the written 
consent of the subjects. Subjects who gave consent were asked to provide their telephone number 
and were subsequently contacted by trained interviewers (from the Social Science Research 
Centre, the University of Hong Kong) who blindly recruited the subjects by telephone within two 
weeks (the baseline), and conducted blind follow-ups 2 weeks after the baseline interviews and 
at the 26-week mark after the baseline interviews. Telephone interviews were used to enhance 
response and completion rates as interviews could be conducted at a more convenient time for 
the respondents and reduces service disruption [17]. To maintain the quality of the data, all study 
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instruments were read verbatim in a standardized way. Subjects were contacted using a 
computer-aided telephone interviewing system by the interviewers between 10:00 am and 10:30 
pm on weekdays up to a maximum of five attempts. 
 
Study instruments 
The IPSS (Hong Kong Chinese version 2) 
The IPSS (Hong Kong Chinese version 2) contains seven questions regarding symptoms 
(incomplete bladder emptying, frequency of urination, intermittency, urgency, weak urine 
stream, straining and nocturia) and one LUTS-specific HRQOL question. Higher scores indicate 
poorer HRQOL and more severe LUTS. The psychometric properties including the validity, 
reliability, sensitivity and responsiveness of the IPSS have been confirmed in Chinese primary 
care patients[15, 16]. The total symptom score ranges from 0 to 35. A total symptom score less 
than or equal to 7 is mild, 8-19 represents moderate symptoms, and 20-35 represents severe 
symptoms. The IPSS Voiding sub-score (IPSS-V, the sum of scores from incomplete bladder 
emptying, intermittency, weak stream and straining) and IPSS Storage sub-score (IPSS-S, sum of 
scores from frequency, urgency and nocturia) are computed to calculate the IPSS voiding-to-
storage sub-score ratio (IPSS V/S). Responses to the HRQOL question range from 0 to 6. 
The Short Form-12 Health Survey Version 2 (SF-12v2) 
The SF-12v2 is a generic HRQOL measure that covers eight domains namely physical 
functioning (PF), role limitation due to physical problems (RP), bodily pain (BP), general health 
(GH), vitality (VT), social functioning (SF), role limitation due to emotional problems (RE) and 
mental health (MH) [18]. The domain scores are calculated by the sum of the relevant item 
scores and their transformation into a representative range from 0 to 100 [19]. The SF-12v2 can 
be summarized into physical and mental component summary scores (PCS and MCS) with 
higher scores indicating a better HRQOL. The population norm of the SF-12 v2 has been 
established for Chinese adults in Hong Kong [20, 21]. 
Depression Anxiety Stress Scale 21 (DASS-21) 
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DASS-21 contains 3 scales to measure depression, anxiety and stress. Each scale consists of 7 
questions. The multiplied scores can be categorized as normal, mild, moderate, severe and 
extremely severe as defined in the DASS manual. Several studies have been conducted to show 
the validity and reliability of the scale [22, 23]. The scale has been applied in both clinical and 
non-clinical settings [24, 25]. The correlations between the scale and the quality of life question 
of the IPSS were assessed. 
Socio-demographic information 
Socio-demographic information including age, education, monthly household income, and 
marital status was asked. 
Clinical information  
The parameters of urodynamic variables including the maximum urinary flow rate (Qmax), post-
void residual urine and voided volume were retrieved from paper or electronic medical records.  
 
Sample size calculation 
The sample size for comparing the mean difference of the IPSS between the baseline and the 26-
week follow-up in patients with BPH was estimated. A sample size of 130 patients in total was 
needed to have a 0.3 effect size, 80% power and 95% confidence interval with the a 30% 
attrition rate using a paired t-test. The sample size for the control group was estimated. A sample 
size of 85 patients in the control group was needed to have 0.85 required area under the curve 
(AUC) of the receiver operating characteristic (ROC) with 0.03 standard error [8, 26].  
 
Data Analysis 
Descriptive statistics, including the mean, standard deviation, and percentage of floor and ceiling 
scores were calculated. 15% was used as the threshold for a significant floor or ceiling effect 
[27]. The internal construct validity of the IPSS was assessed by examining the corrected item-
total scale correlation using the corrected item-total scale correlation scores of ≥0.4 to identify an 
adequate correlation [28]. The convergent validity of the IPSS HRQOL and total symptom 
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scores were assessed using Pearson’s correlation test against the SF-12v2 and DASS-21. It was 
hypothesized that the IPSS HRQOL score would have statistically significant correlations with 
SF-12v2 MCS and the PCS scores and DASS-21 scores, respectively. The convergent validity of 
the IPSS total symptom score was assessed using Pearson’s correlation test against the Qmax, 
post-void residual urine and voided volume, respectively. It was hypothesized that the IPSS 
HRQOL score would have statistically significant correlations with Qmax, post-void residual 
urine and voided volume, respectively. The internal consistency of the IPSS was assessed using 
Cronbach’s alpha using cut-off scores of ≥ 0.7 to indicate adequate internal consistency [29]. 
Test-retest reliability was assessed by examining the intra-class correlation (ICC) coefficient. 
ICC ≥ 0.7 was used to indicate good reproducibility [27]. The sensitivity of the IPSS was 
determined by performing known group comparisons of the mean total symptom and HRQOL 
scores by conducting an independent t-test and by calculating the area under the receiver 
operating characteristic curve (AUC). It was hypothesized that (i) subjects with BPH would have 
higher symptom scores and poorer health-related quality of life than control subjects and (ii) the 
IPSS would be able to determine and differentiate patients with LUTS and those without LUTS, 
with an AUC of >0.7. To assess the responsiveness of the IPSS, the change in the mean scores of 
the IPSS between the baseline and the 26-week mark interviews were examined conducting a 
paired t-test. The IPSS score differences between the baseline and 26-week interviews were 
evaluated by standardized effect size (SES) [30], and the standardized response mean (SRM) 
[31]. The effect size statistics can provide a clear interpretation of the magnitude of the change. 
All statistical analyses were conducting using SPSS version 23.0. A P-value of less than 0.05 
was considered to be of statistical significance. 
 
Ethics 
The study protocol was approved by the institutional review board of The University of Hong 
Kong and the Hong Kong Hospital Authority for the Hong Kong West Cluster (reference: UW 
14-058), Kowloon West Cluster (reference: KW/EX-14-032 (72-08)) and the New Territories 
West Cluster (reference: NTWC/CREC/1259/14). 
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All procedures of the study involving human participants were performed in accordance with the 
ethical standards of the institutional and/or national research committee and with the 1964 
Helsinki Declaration and its later amendments or comparable ethical standards. Written consent 
was obtained from all individual participants involved in the study. 
  




Baseline sociodemographic information 
A total of 297 subjects were invited to participate in this observational study. From this total, 60 
subjects refused to give consent to participate in the study, whereas the remaining 237 subjects 
were recruited in the study. Out of those 237 subjects, 163 (100, 61.3% for the BPH group and 
63, 38.7% for the control group) completed the baseline interview. Compared to the control 
group, subjects with BPH were older (mean age of 69.1, SD 9.09 vs. mean age of 57.1, SD 12.6, 
p-value <0.01) , were less likely to be actively employed (26% vs. 54.0%, p-value<0.01); had a 
lower household income (80.4% vs. 54.8%, p-value<0.01) , were less likely to smoke (85.0% vs. 
65.1%, p-value <0.01) , and had had a stroke (6.0% vs. 0%, p-value<0.05). The baseline 
characteristics of study subjects are shown in Table 1.  
Descriptive statistics and floor and ceiling effects 
Table 2 shows the descriptive statistics of SF-12v2, IPSS and DASS-21 scores. With regards to 
the IPSS total symptom score and IPSS-S, 1.89% of the subjects had the lowest possible score 
whilst 0.63% of subjects had the highest possible score. With regards to the IPSS-V, it had a 
relatively higher floor effect (21.6%) but a lower ceiling effect (0.62%). With regards to the IPSS 
HRQOL score, 1.84% of subjects had the lowest possible score while 4.29% of subjects had the 
highest possible score.  
Construct validity  
Table 3 shows the results of the corrected item-total correlation testing for the items regarding 
urinary symptoms. Corrected item-total correlation scores were ≥0.4 for all symptoms, except in 
the case of nocturia (correlation coefficient: 0.309). Pearson’s correlation testing of the IPSS 
total symptom score against clinical parameters (voided volume, post-void residual urine and 
Qmax) , and the IPSS HRQOL score against the SF-12v2 and DASS-21 scores were then tested. 
The correlations between the IPSS total symptom score and clinical parameters were not 
statistically significant. On the other hand, there were significant correlations between the IPSS 
HRQOL score, SF-12v2 and DASS-21 scores. However, the IPSS HRQOL score was weakly 
correlated with SF-12v2 PCS (correlation coefficient: -0.30) and MCS (correlation coefficient: -
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0.26), and the DASS-21 Depression (correlation coefficient: 0.32), Anxiety (correlation 
coefficient: 0.31) and Stress (correlation coefficient: 0.30) scores respectively. 
 
Reliability  
The internal consistency and test-retest reliability of the IPSS were then performed. With regards 
to the IPSS total symptom score, it increased from 13.61 to 14.24 while the HRQOL score 
decreased from 3.11 to 2.99 from the baseline. Both are considered insignificant. Cronbach’s 
alpha coefficient was 0.90 for the seven symptom-related items. The ICC of the IPSS total 
symptom score and HRQOL score were 0.90 and 0.86, respectively.  
Sensitivity  
A statistically significant difference was detected between the BPH group and non-BPH group 
for the IPSS total symptom score (effect size 0.68) but not the HRQOL score. Moreover, there 
was no significant difference between groups for all the SF-12v2 and DASS-21 scores. 
Furthermore, the area under the ROC curve was 0.67 (95% CI: 0.584, 0.757) and 0.60 (95% CI: 
0.506, 0.689) with regards to the IPSS total symptom score and HRQOL score, respectively. 
Figure 1 depicts the area under the ROC curve and the discriminative power of the IPSS total 
symptom and HRQOL scores in the differentiation of the BPH and control groups. Figure 2 
shows the ability of the IPSS scores, SF-12v2 scores and DASS-21 scores when discriminating 
between benign prostatic hyperplasia and control patients by the independent t-test.  
Responsiveness  
Table 4 shows the results of the responsiveness analysis using the paired-t-test and 
responsiveness statistics. There were no significant differences between the IPSS total symptom 
score, IPSS-V, IPSS-S, IPSS-V/S and HRQOL scores; SF-12v2 PCS and MCS scores; and 
DASS-21 Depression, Anxiety and Stress scores. 
Table 5 shows the responsiveness properties of the HRQOL instruments in a subgroup of 
patients with improved health status over a 6-month period. Improvements in the IPSS total 
symptom score, and the IPSS-V, IPSS-S and HRQOL scores were statistically significant and 
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corresponded to a medium-sized change effect. Changes in the IPSS-V/S; SF-12v2 PCS and 
MCS scores, and the DASS-21 Depression, Anxiety and Stress scores were small-sized and 
therefore statistically insignificant.  
 
Discussion 
The purpose of this study is to evaluate psychometric properties including validity, reliability, 
sensitivity and responsiveness of the IPSS instrument in male patients with BPH under 
secondary care. Although this is not the first study to validate the IPSS in a Chinese population, 
the current study was designed to build upon previous research to provide more information on 
the psychometric properties of the IPSS.  
The lack of significant floor and ceiling effects of the IPSS indicated that this measure has the 
potential capability to capture any deterioration or improvement of LUTS and HRQOL. 
In item-total correlation testing, the symptom-related item of nocturia had a poor correlation. The 
result suggest that this item is being measured in a related yet slightly different domain than the 
other items of the IPSS. This result is similar to that of a previous validation study carried out on 
subjects under primary care in Hong Kong [15]. 
Contrary to the hypothesis, the IPSS total symptom score did not present any statistically 
significant correlations with objective parameters including Qmax, voided volume and post-void 
residual urine. The findings implied that there were distinct differences between objective 
clinical parameters and perceived symptom severity.  Therefore, both clinical parameters and the 
IPSS should be combined and supplement one another. These findings have supplemented the 
previous Hong Kong study [15] which did not test the correlation between the IPSS total 
symptom score and objective clinical parameters. 
The IPSS HRQOL score had a weak correlation with SF-12v2 PCS and MCS scores suggesting 
that there is a difference between the construct of the IPSS HRQOL question and that of the SF-
12v2. Since SF-12v2 is a generic HRQOL measure, the domains of such measures might not be 
specific nor sensitive enough to capture the impact of LUTS on HRQOL. Generic measures 
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contain irrelevant domains and may miss specific concerns of the respondents [32]. The results 
support the added value of condition-specific measures. 
The IPSS was found to be a reliable measure for patient-reported outcome. The internal 
consistency (Cronbach’s alpha >0.7) of the IPSS appears to be comparable to the original 
English instrument [8]. The 2-week test-retest reliability was acceptable and comparable to other 
versions of the IPSS [8, 15, 26, 33]. 
The findings of higher severity IPSS total symptoms severity in patients with BPH compared to 
the non-BPH group showed that the total symptom score was sensitive in differentiating patients.  
The area under the ROC curve was just short of 0.7 (0.67) but still acceptable. Unexpectedly, the 
IPSS HRQOL question was not sensitive enough to differentiate subjects. The single item 
question seemingly does not suffice. Thus, clinicians and researchers should not rely on the IPSS 
single-item HRQOL for screening. Expectedly, the SF-12v2 and DASS-21 was not sensitive 
enough to differentiate patients due to the generic nature of these measures. 
Limitations 
Subjects in the present study were only recruited by a convenience sampling in three government 
funded urology specialist clinics. The psychometric performance of these measures should be 
further tested with Putonghua speakers or Chinese speakers of different nationalities as the 
subjects in this study were mainly Cantonese speakers.  
Conclusion 
The IPSS is a valid and reliable measure among Chinese patients with BPH. The IPSS total 
symptom score, but not the HRQOL score, is sensitive in differentiating subgroups.  
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Figure 1. Receiver operating characteristics curves of the IPSS total symptom and HRQOL 
scores 
Figure 2. Ability of IPSS scores, SF-12v2 scores and DASS-21 scores in discriminating between 
benign prostatic hyperplasia and control patients by the independent t-test 
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Table 1. Baseline characteristics at baseline between BPH participants and control patients 
  Total (N = 163) 
BPH patients 
(N = 100) 
Control Patients 
(N = 63) P-value 
Socio-Demographic (%, n)     
Age (mean ± SD) 64.50±12.05 (163) 69.14±9.09 (100) 57.14±12.55 (63) <0.001* 
Marital Status    0.383 
Not Married 8.70 % (14) 7.14 % (7) 11.11 % (7)  
Married 91.30 % (147) 92.86 % (91) 88.89 % (56)  
Employment Status    <0.001* 
Not Working 63.19 % (103) 74.00 % (74) 46.03 % (29)  
Currently working 36.81 % (60) 26.00 % (26) 53.97 % (34)  
Household Income    <0.001* 
< $20,000 70.13 % (108) 80.43 % (74) 54.84 % (34)  
≥ $20,000 29.87 % (46) 19.57 % (18) 45.16 % (28)  
Smoking Status    0.003* 
Non-Smoker 77.30 % (126) 85.00 % (85) 65.08 % (41)  
Smoker 22.70 % (37) 15.00 % (15) 34.92 % (22)  
Drinking Status    0.736 
Non-Drinker 64.97 % (102) 65.98 % (64) 63.33 % (38)  
Drinker 35.03 % (55) 34.02 % (33) 36.67 % (22)  
Voided volume (mean ± SD) 245.31±128.73 (81) 245.31±128.73 (81) NA NA 
Post void residual urine  
(mean ± SD) 86.36±91.08 (81) 86.36±91.08 (81) NA NA 
Qmax (mean ± SD) 12.61±7.19 (77) 12.61±7.19 (77) NA NA 
Co-morbidities (%, n)     
Hypertension 52.47 % (85) 49.00 % (49) 58.06 % (36) 0.261 
Diabetes 16.15 % (26) 16.16 % (16) 16.13 % (10) 0.996 
Cardiovascular Disease 20.00 % (32) 24.49 % (24) 12.90 % (8) 0.074 
Stroke 3.68 % (6) 6.00 % (6) 0.00 % (0) 0.048* 
Respiratory diseases  7.45 % (12) 6.12 % (6) 9.52 % (6) 0.423 
Cancer 4.91 % (8) 5.00 % (5) 4.76 % (3) 0.945 
Kidney diseases  5.88 % (9) 7.00 % (7) 3.77 % (2) 0.420 
Psychiatric disorders 4.35 % (7) 3.03 % (3) 6.45 % (4) 0.300 
Other major diseases 25.15 % (41) 22.00 % (22) 30.16 % (19) 0.242 
BPH= benign prostatic hyperplasia; Qmax=maximum urinary flow rate; NA=Not applicable  
Note: 
* Significant at a level of 0.05 by chi-square test or independent t-test as appropriate 
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Table 2. Descriptive statistics of IPSS, SF-12v2 scores and DASS-21 scores at baseline  





IPSS scores (mean ± SD, n)    
IPSS Total Symptom Score (min 0 - max 35) 13.03 ± 8.09 (159) 1.89% 0.63% 
IPSS Voiding subscore (min 0 - max 20) 6.58±5.54 (162) 21.60% 0.62% 
IPSS Storage subscore (min 0 - max 15) 6.34±3.58 (159) 1.89% 0.63% 
IPSS Voiding-to-storage subscore ratio 1.17±1.15 (156) NA 
IPSS HRQOL Score (min 0 - max 6) 2.99 ± 1.69 (163) 1.84% 4.29% 
SF-12v2 Scores (mean ± SD, n)  
  
PCS 44.05 ± 11.20 (163) 0.61% 0.61% 
MCS 53.00 ± 11.18 (163) 0.61% 0.61% 
DASS-21 scores (mean ± SD, n)    
DASS Depression Score (min 0 - max 21) 2.01 ± 3.22 (163) 47.85% 0.61% 
DASS Anxiety Score (min 0 - max 21) 2.28 ± 2.53 (163) 25.77% 0.61% 
DASS Stress Score (min 0 - max 21) 2.44 ± 3.34 (163) 41.72% 0.61% 
PCS = Physical Component Summary; MCS = Mental Component Summary; MH = Mental Health;  
HRQOL = health-related quality of Life; IPSS = International Prostate Symptom Score;  
DASS = Depression Anxiety Stress Scales; NA = Not Applicable 
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Table 3. Corrected item-scale correlation of the IPSS  
  
Eligible Patients (N=163) 
n mean ± SD 
Corrected item-total 
correlation 
IPSS symptom score 
Incomplete emptying 162 2.062 ± 1.806 0.577 
Frequency 162 2.438 ± 1.642 0.517 
Intemittency 162 1.556 ± 1.759 0.589 
Urgency 162 1.667 ± 1.712 0.583 
Weak Stream 163 1.681 ± 1.797 0.651 
Straining 163 1.294 ± 1.732 0.553 
Nocturia 161 2.199 ± 1.382 0.309 
IPSS = International Prostate Symptom Score  
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Change ± SD  
P-value SES SRM 
IPSS (mean ± SD)      
Total Symptom Score 13.66 ± 7.62 12.67 ± 8.28 -0.99 ± 6.60 0.161 0.13 0.15 
Voiding subscore 6.94±5.38 6.62±5.80 -0.32±4.41 0.490 0.06 0.07 
Storage subscore 6.64±3.38 5.98±3.64 -0.66±3.17 0.052 0.20 0.21 
Voiding-to-storage 
subscore ratio 
1.11±0.90 1.25±1.19 0.15±0.96 0.158 0.16 0.15 
HRQOL Score 3.01 ± 1.72 2.77 ± 1.75 -0.24 ± 1.64 0.162 0.14 0.15 
SF-12v2 (mean ± SD)      
PCS 43.64±10.90 43.16±12.62 -0.48 ± 8.42 0.585 0.04 0.06 
MCS 52.41±11.86 52.02±12.19 -0.39 ± 11.18 0.743 0.03 0.03 
DASS-21 (mean ± SD)      
DASS Depression 
Score 
2.27 ± 3.42 2.43 ± 3.70 0.15 ± 2.00 0.465 0.04 0.08 
DASS Anxiety Score 2.54 ± 2.57 2.46 ± 2.71 -0.08 ± 1.79 0.683 0.03 0.04 
DASS Stress Score 2.66 ± 3.69 2.65 ± 3.69 -0.01 ± 2.07 0.960 0.00 0.01 
              
IPSS = International Prostate Symptom Score; DASS = Depression Anxiety Stress Scales; 
SES = Standardized Effect Size; SRM = Standardized Response Mean; 
PCS = Physical Component Summary; MCS = Mental Component Summary 
Note: 
*Significant difference (P<0.05) on score between baseline and 6-month follow-up by paired t-test 
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Table 5. Responsiveness to change over time from baseline to 6-month follow-up among 







Change ± SD  
P-value SES SRM 
IPSS (mean ± SD)      
Total Symptom Score 15.35±8.42 10.81±8.11 -4.54±8.28 0.010* 0.54 0.55 
Voiding subscore 7.88±5.29 5.12±5.35 -2.77±5.19 0.012* 0.52 0.53 
Storage subscore 7.46±3.57 5.69±3.46 -1.77±3.88 0.029* 0.50 0.46 
Voiding-to-storage 
subscore ratio 
0.99±0.53 0.84±0.85 -0.15±0.97 0.432 0.29 0.16 
HRQOL Score 3.22±1.85 2.48±1.63 -0.74±1.81 0.043* 0.40 0.41 
SF-12v2 (mean ± SD)      
PCS 42.91±11.68 44.51±11.71 1.6±9.53 0.391 0.14 0.17 
MCS 50.96±12.47 50.78±13.26 -0.17±12.68 0.944 0.01 0.01 
DASS-21 (mean ± SD)      
DASS Depression 
Score 
2.56±3.53 2.48±4.16 -0.07±2.30 0.869 0.02 0.03 
DASS Anxiety Score 3.04±2.98 2.78±3.25 -0.26±2.40 0.579 0.09 0.11 
DASS Stress Score 3.04±3.75 2.96±4.32 -0.07±2.56 0.881 0.02 0.03 
              
IPSS = International Prostate Symptom Score; DASS = Depression Anxiety Stress Scales; 
SES = Standardized Effect Size; SRM = Standardized Response Mean; 
PCS = Physical Component Summary; MCS = Mental Component Summary 
Note:  
*Significant difference (P<0.05) on score between baseline and 6-month follow-up by paired t-test 
 
Figure 1. ROC curves of IPSS total symptom and HRQOL scores 
 
 
Figure 2. Ability of IPSS scores, SF-12v2 scores and DASS-21 scores in discriminating between benign prostatic hyperplasia and control patients by 
the independent t-test 
 
  
 
 
